Skip to content

About US
About LB-102
Pipeline
Publications
Investors
Careers
Contact Us

American Society of Clinical Psychopharmacology 2025 Annual Meeting

May 27, 2025

– May 30, 2025

Scottsdale, Arizona

Oral, Once-Daily LB-102: Recent Positive Results From a Phase 2 Study in Patients With Acute Schizophrenia

view ALL Events

About US
About LB-102
Pipeline
Publications
Investors
Careers
Contact Us

About US
About LB-102
Pipeline
Publications
Investors
Careers
Contact Us

All Rights Reserved.

About Us
Management
Board of Directors
Scientific Advisory Board
Careers
Contact Us

About LB-102
Pipeline
About Schizophrenia
Publications

Investors Overview
News
Events
Corporate Governance
SEC Filings
Stock Information
Investor FAQs

© 2025 LB Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.

Scroll to Top